The Technical Analyst
Caladrius Biosciences, [CLBS]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Caladrius Biosciences, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-16.75% $0.426
/ 15 sep 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.35 mill |
| EPS: | -0.394 |
| P/E: | -1.082 |
| Earnings Date: | Nov 02, 2022 |
| SharesOutstanding: | 7.86 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2022-10-07 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.082 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.082 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.397 - 0.455 ( +/- 6.80%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-09-01 | Buck Kristen K | Buy | 58 000 | Common Stock |
| 2022-09-01 | Buck Kristen K | Sell | 44 776 | Common Stock |
| 2022-09-01 | Mazzo David J | Buy | 150 000 | Common Stock |
| 2022-09-01 | Mazzo David J | Sell | 69 742 | Common Stock |
| 2022-01-13 | Mazzo David J | Sell | 6 471 | Common Stock |
| INSIDER POWER |
|---|
| 28.99 |
| Last 95 transactions |
| Buy: 2 781 590 | Sell: 342 279 |
Forecast:
01:40 - $0.515
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.426 (-16.75% ) |
| Volume | 26.95 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CLBS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CLBS
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Latest Press Releases
2022-06-08 08:00:00 - Press Release
Caladrius Biosciences To Present At The Bio International Convention 2022
Basking ridge, n.j., june 08, 2022 (globe newswire) -- caladrius biosciences, inc. (nasdaq: clbs) (“caladrius” or the “company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that david j. mazzo, ph.d., president and chief executive officer of caladrius, will present a corporate overview at the bio international convention being held in-person at the san diego convention center in san diego, ca, from june 13-16, 2022.
2022-05-18 08:00:00 - Press Release
Caladrius Biosciences To Present At The H.c. Wainwright Global Investment Conference
Basking ridge, n.j., may 18, 2022 (globe newswire) -- caladrius biosciences, inc. (nasdaq: clbs) (“caladrius” or the “company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that david j. mazzo, ph.d., president and chief executive officer of caladrius, will present a corporate overview at the h.c. wainwright global investment conference being held both virtually and in-person at the fontainebleau miami beach hotel in miami, fl on may 23-26, 2022.
2022-05-09 09:00:00 - Press Release
Shareholder Investigation: Halper Sadeh Llp Investigates Gtyh, Clbs, Igny, Twtr
New york , may 9, 2022 /prnewswire/ -- halper sadeh llp, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: gty technology holdings inc. (nasdaq: gtyh) 's sale to gi partners for $6.30 in cash per share. if you are a gty technology shareholder, click here to learn more about your rights and options.
2022-03-15 08:00:00 - Press Release
Caladrius Biosciences To Host Fourth Quarter And Full Year 2021 Financial Results Conference Call On Tuesday, March 22, 2022, At 4:30 P.m. Eastern Time
Basking ridge, n.j., march 15, 2022 (globe newswire) -- caladrius biosciences, inc. (nasdaq: clbs) (“caladrius” or the “company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the company will report its financial results for the three months and twelve months ended december 31, 2021, on tuesday, march 22, 2022, at 4:30 p.m. (et). to join the live conference call, please refer to the dial-in information provided below.
2022-01-04 16:05:00 - Press Release
Caladrius Biosciences Announces Participation In Upcoming Conferences In January 2022
Basking ridge, n.j., jan. 04, 2022 (globe newswire) -- caladrius biosciences, inc. (nasdaq: clbs) (“caladrius” or the “company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced its participation in several industry and investor events. all presentations are pre-recorded and available on-demand through the online conference platforms.
Latest News
2022-08-04 22:59:06 - Seeking Alpha
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript
Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO Kristen Buck - EVP, Research and Development & CMO James Nisco - VP, Finance & Treasury Conference Call Participants Kumar Raja - Brookline Capital Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences' Second Quarter 2022 Financial Results and Business Update Conference Call. Currently all participants are in listen-only mode.
2022-06-08 08:00:00 - GlobeNewsWire
Caladrius Biosciences to Present at the BIO International Convention 2022
BASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the BIO International Convention being held in-person at the San Diego Convention Center in San Diego, CA, from June 13-16, 2022.
2022-05-18 08:00:00 - GlobeNewsWire
Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference
BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the H.C. Wainwright Global Investment Conference being held both virtually and in-person at the Fontainebleau Miami Beach Hotel in Miami, FL on May 23-26, 2022.
2022-05-05 23:29:07 - Seeking Alpha
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call Transcript
Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Menditto - VP, Investor Relations & Corporate Communications David Mazzo - President & Chief Executive Officer James Nisco - Vice President of Finance & Treasury Kristen Buck - Chief Medical Officer Conference Call Participants Kumar Raja - Brookline Capital Markets Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences First Quarter 2022 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.
2022-04-27 12:25:05 - Benzinga
Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics
Caladrius Biosciences Inc (NASDAQ: CLBS) and privately-held Cend Therapeutics Inc have agreed to merge in an all-stock approximate "merger of equals" transaction approved by the Boards of Directors of each company. The transaction values each company at $90.
2022-03-22 20:52:04 - Seeking Alpha
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2021 Results - Earnings Call Transcript
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2021 Results - Earnings Call Transcript
2022-03-15 08:00:00 - GlobeNewsWire
Caladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three months and twelve months ended December 31, 2021, on Tuesday, March 22, 2022, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below.
2022-01-04 16:05:00 - GlobeNewsWire
Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022
BASKING RIDGE, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced its participation in several industry and investor events. All presentations are pre-recorded and available on-demand through the online conference platforms.
2022-01-04 14:27:18 - PennyStocks
Hot Penny Stocks For 2022 To Buy For Under $2
Penny stocks to buy for under $2 The post Hot Penny Stocks For 2022 To Buy For Under $2 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-11-04 19:44:06 - Seeking Alpha
Caladrius Biosciences Inc.'s (CLBS) CEO David Mazzo on Q3 2021 Results - Earnings Call Transcript
Caladrius Biosciences Inc.'s (CLBS) CEO David Mazzo on Q3 2021 Results - Earnings Call Transcript